Trevi Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Trevi Therapeutics

12/05/2022 23:36

* Trevi Therapeutics Inc  TRVI.OQ  reported a quarterly
adjusted
loss of 24 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 29 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Trevi Therapeutics Inc's reported EPS for the quarter was
a loss
of 24 cents​.
    * The mean earnings estimate of analysts had risen by
about 33.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Trevi Therapeutics Inc shares had fallen by 10.0% this
quarter and gained 153.1% so far this year.
    * The company reported a quarterly loss of $7.33 million.
    * Wall Street's median 12-month price target for Trevi
Therapeutics Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 10:35 p.m.  ​All
figures in US dollars unless otherwise stated